496
Participants
Start Date
December 30, 2020
Primary Completion Date
September 6, 2024
Study Completion Date
September 6, 2024
UCB0599
Drug: UCB0599 Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive UCB0599 in a pre-specified sequence during the Treatment Period.
Placebo
Drug: Placebo Pharmaceutical form: Capsules Route of administration: Oral use Participants will receive Placebo in a pre-specified sequence during the Treatment Period.
Pd0053 50077, New York
Pd0053 50521, New York
Pd0053 50119, New York
Pd0053 50530, Stony Brook
Pd0053 50535, Williamsville
Pd0053 50526, Philadelphia
Pd0053 50547, Baltimore
Pd0053 50410, Fairfax
Pd0053 50542, Charlottesville
Pd0053 50534, Virginia Beach
Pd0053 50402, Crab Orchard
Pd0053 50084, Charleston
Pd0053 50199, Miami
Pd0053 50396, Boca Raton
Pd0053 50394, Tampa
Pd0053 50524, Bradenton
Pd0053 50140, Birmingham
Pd0053 50532, Knoxville
Pd0053 50543, Memphis
Pd0053 50255, Columbus
Pd0053 50527, Toledo
Pd0053 50372, Cleveland
Pd0053 50311, Cleveland
Pd0053 50386, Farmington Hills
Pd0053 50549, Iowa City
Pd0053 50536, Saint Paul
Pd0053 50399, Winfield
Pd0053 50401, Chicago
Pd0053 50074, Kansas City
Pd0053 50395, New Orleans
Pd0053 50539, Little Rock
Pd0053 50398, Tulsa
Pd0053 50113, Houston
Pd0053 50400, San Antonio
Pd0053 50531, Englewood
Pd0053 50081, Phoenix
Pd0053 50391, Tucson
Pd0053 50397, Las Vegas
Pd0053 50416, La Jolla
Pd0053 50519, Fountain Valley
Pd0053 50385, Fresno
Pd0053 50510, Portland
Pd0053 50419, Spokane
Pd0053 50506, Phoenix
Pd0053 50118, Los Angeles
Pd0053 50392, Danbury
Pd0053 50538, Farmington
Pd0053 50544, Augusta
Pd0053 50310, Chicago
Pd0053 50121, Lexington
Pd0053 50529, Baltimore
Pd0053 50243, Boston
Pd0053 50546, Worcester
Pd0053 50299, New Brunswick
Pd0053 50525, Houston
Pd0053 50107, Burlington
Pd0053 50292, Kirkland
Pd0053 50374, Calgary
Pd0053 50390, Kelowna
Pd0053 50387, Ottawa
Pd0053 50389, Toronto
Pd0053 40197, Amiens
Pd0053 40527, Bordeaux
Pd0053 40424, Créteil
Pd0053 40526, Lille
Pd0053 40130, Marseille
Pd0053 40635, Nantes
Pd0053 40524, Nîmes
Pd0053 40525, Paris
Pd0053 40131, Strasbourg
Pd0053 40528, Toulouse
Pd0053 40515, Berlin
Pd0053 40138, Bonn
Pd0053 40530, Dresden
Pd0053 40711, Erbach im Odenwald
Pd0053 40023, Erlangen
Pd0053 40710, Essen
Pd0053 40532, Haag in Oberbayern
Pd0053 40024, Hanover
Pd0053 40249, Kiel
Pd0053 40174, Mainz
Pd0053 40529, Marburg
Pd0053 40531, Regensburg
Pd0053 40555, Brescia
Pd0053 40533, Padua
Pd0053 40257, Roma
Pd0053 40534, Roma
Pd0053 40697, Roma
Pd0053 40359, Nijmegen
Pd0053 40694, Bydgoszcz
Pd0053 40719, Jelenia Góra
Pd0053 40539, Katowice
Pd0053 40538, Krakow
Pd0053 40696, Krakow
Pd0053 40700, Lodz
Pd0053 40702, Lublin
Pd0053 40535, Oświęcim
Pd0053 40536, Warsaw
Pd0053 40699, Warsaw
Pd0053 40705, Warsaw
Pd0053 40045, A Coruña
Pd0053 40159, Barcelona
Pd0053 40267, Barcelona
Pd0053 40046, Córdoba
Pd0053 40540, Madrid
Pd0053 40542, Móstoles
Pd0053 40352, Pamplona
Pd0053 40541, San Sebastián
Pd0053 40049, Seville
Pd0053 40175, London
Pd0053 40543, London
Pd0053 40698, London
Pd0053 40544, Motherwell
Pd0053 40306, Newcastle upon Tyne
Pd0053 40457, Plymouth
The Parkinson Study Group
NETWORK
UCB Biopharma SRL
INDUSTRY